Tela Bio, Inc. · NASDAQ:TELA
Tela Bio — Investor Presentation (March 2025)
22 slides from Tela Bio's investor presentation, Mar 20, 2025
Slide 1: Investor Presentation March 2025
INVESTOR PRESENTATION March 2025
Slide 2: Forward-looking statements
This presentation contains forward - looking statements within the meaning of The Private Securities Litigation Reform Act of 1995 . All statements other than statements of historical facts contained in this document, including but not limited to statements regarding possible or assu med future resu
Slide 3: Our Mission
We provide innovative soft - tissue reconstruction solutions that optimize clinical outcomes by prioritizing the Preservation and Restoration of the patient’s own anatomy. 3 Our Mission
Slide 4: Advanced reinforced tissue matrix portfolio supported by compelling clinical evidence
TELA Bio, Inc. Advanced reinforced tissue matrix portfolio supported by compelling clinical evidence $2.6B US market opportunity 1 – still in early stages of growth Driving commercial adoption with targeted direct - sales approach Recent product launches in growing markets: robotic hernia surgery, p
Slide 5: Product Adoption Since Launch
Product Adoption Since Launch 65,000+ OviTex Reinforced Tissue Matrix (RTM) Implantations Globally 23 40+ Published or Presented Works 6,000+ Hospitals Covered by GPO Access 15,000 OviTex PRS Implantations Globally ~
Slide 6: Reinforced Tissue Matrix
REINFORCED TISSUE MATRIX @TELABIO SCIENCE. VALUE. INNOVATION. 5
Slide 7: ~$1.8 Billion Annual Opportunity US Hernia Surgery Market
Complex, Moderate Ventral / Abdominal Wall Reconstruction Simple Ventral Hernia Repair Inguinal Hernia Repair Hiatal Hernia Repair ~105,000 ~395,000 ~645,000 ~42,000 $630 M $590 M $ 54 0 M $42 M 1. Sources: Millennium Research Group Reports, IMS Health Data; iData Research MedSKU . 2. Management est
Slide 8: OviTex Reinforced Tissue Matrix: A more Natural Hernia Repair
OviTex Core 4 - layer device No smooth sides Robot Compatible 1 : Yes OviTex Core is designed to reinforce primary hernia repairs where the device will not come into contact with viscera. A more Natural Hernia Repair OviTex Reinforced Tissue Matrix OviTex 1S 6 - layer device 1 smooth side Robot Comp
Slide 9: Surgeon and patient survey and hernia mesh litigation
8 1. Hernia and Abdominal Surgeries Survey (Oct 2020). A group of 71 surgeons were surveyed regarding use of mesh in various he rni a repair surgeries. 2. Figures derived from Company - sponsored online poll of approximately 1,100 potential patients for hernia procedures. 3. See Medtronic plc Form 1
Slide 10: Consistently Low Recurrence Rates
Source: Refer to “Clinical References” in this presentation. * Indicates one or more surgeons are paid consultants of TELA Bio, Inc. 9 Backed by 8+ years of clinical experience and 40+ published or presented works Consistently Low Recurrence Rates
Slide 11: Clinical outcomes compared to polypropylene and biologics
*Overall complications including surgical site occurrences (SSOs) and surgical site infections (SSIs) a – OviTex patients were more complicated with a significantly higher mVHWG distribution and CDC wound classification compared to polypropylene patients. b – OviTex patients experienced significantl
Slide 12: Clinical outcomes compared to resorbable synthetics and biologics
* Kaplan - Meier survival estimate **No head - to - head clinical studies have been conducted. Due to differences in patient population, surgeons, surgical technique, and other variables, no direct comparisons of results can be made. For a comparative discussion of these studies, please see G. DeNot
Slide 13: Hernia Market Evolution
TELA Bio positioned to grow from a market shift towards resorbable and more “natural repair” solutions as an alternative to traditional Permanent Synthetics or Biologics Hernia Market Evolution 2027 2021 2018 2013 Permanent Synthetic Biologic Sales Market Share <1% Robotic Procedures ( Px ) 7% Robot
Slide 14: OviTex PRS Reinforced Tissue Matrix
OVITHX PRS REINFORCED TISSUE MATRIX @TELABIO’ SCIENCE. VALUE. INNOVATION. 43
Slide 15: ~$800 Million Annual Opportunity US Plastic & Reconstructive Surgery Market
14 ~$800 Million Annual Opportunity US Plastic & Reconstructive Surgery Market $700M 2 1. OviTex PRS is for implantation to reinforce soft tissue where weakness exists in patients requiring soft tissue repair or reinforcem en t in plastic and reconstructive surgery. The device is supplied sterile an
Slide 16: OviTex PRS: Specifically designed for plastic and reconstructive surgery
Specifically designed for plastic and reconstructive surgery OviTex PRS An innovative reinforced tissue matrix designed to improve outcomes by facilitating fluid management and controlling degree and direction of stretch Product Features: Layers composed of biologic building block retain biologicall
Slide 17: Leading-edge atraumatic hernia mesh fixation devices
16 Leading - edge atraumatic hernia mesh fixation devices Designed to minimize complications for patient safety and comfort
Slide 18: LIQUIFIX FIX8 & LIQUIFIX Precision
LIQUIFIX FIX8 & LIQUIFIX Precision Atraumatic liquid fixation devices Reduce the need for penetrating mechanical fixation for inguinal and femoral hernia repair Provide precise, controlled adhesive application Addresses an unmet need in the market, less damage to tissue Designed to minimize the risk
Slide 19: Driving Revenue Growth
Driving Revenue Growth Sales Force Size Rep Productivity Product Portfolio GPO Access Clinical Experience X X X X = SALES $ 2021 40 - 45 reps / 5 TB Ltd. 2022 61 reps / 6 TB Ltd. 2023 86 reps / 9 TB Ltd. 2024 63 TMs + 8 ASs / 10 TB Ltd. 2025 (Target) 76 TMs + 21 ASs / 14 TB Ltd. Playbook90 training
Slide 20: Quarterly Revenue and Gross Margin
19 19 +58% +116% +44% +48% +40% +38% +46% +39% +45% +39% +35% +46% +39% +11% +26% +4% 58% 63% 68% 73% 78% 83% $0 $2 $4 $6 $8 $10 $12 $14 $16 $18 $20 1Q21 2Q21 3Q21 4Q21 1Q22 2Q22 3Q22 4Q22 1Q23 2Q23 3Q23 4Q23 1Q24 2Q24 3Q24 4Q24 Gross Margin Revenue ($M) Quarterly Revenue and Gross Margin Revenue Gr
Slide 21: Q4 2024 Performance
19 Delivering Revenue Growth and Strong Margin with Continuing Improvement Potential $18M Quarterly revenue of $17.6M, growing 4% over corresponding period of 2023 $52.7M Cash and Cash Equivalents at December 31, 2024 64% Gross Margin The Company implemented cost - cutting measures in Q3, which are
Slide 22: Clinical References
1. Ankney, C.; Banaschak , C.; Sowers, B.; Szotek , P. Minimizing Retained Foreign Body in Hernia Repair Using a Novel Technique: Reinforced Biologic Augmented Repair ( ReBAR ). J Clin Medical Res 2021, doi:10.37191/mapsci - 2582 - 4333 - 3(4) - 073. 2. Sivaraj , D.; Henn, D.; Fischer, K.S.; Kim, T.